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Summary
Small-molecule inhibitors of protein and lipid kinases
have emerged as indispensable tools for studying
signal transduction. Despite the widespread use of
these reagents, there is little consensus about the
biochemical criteria that define their potency and se-
lectivity in cells. We discuss some of the features that
determine the cellular activity of kinase inhibitors and
propose a framework for interpreting inhibitor selec-
tivity.
Introduction
The dramatic clinical success of Imatinib has fueled an
explosion in kinase-inhibitor discovery research [1]. It
is estimated that kinase inhibitors currently comprise
up to 30% of drug-discovery programs in the pharma-
ceutical industry, and over 50 such compounds are now
in clinical trials [2]. The scale of this investment has
led to the discovery of compounds with properties that
scarcely resemble their early predecessors—picomolar
potency, isoform selectivity, and allosteric binding modes
are increasingly common [3–9]. As these reagents filter
into the hands of scientists engaged in basic research,
they will transform the study of signal transduction.
The first kinase inhibitors were described nearly 20
years ago [2], and a small subset of these compounds
have found widespread application, forming the basis
for much of what we know about the physiological roles
of their targets. As we anticipate a new era of molecu-
larly targeted agents, it is fair to ask what practical les-
sons have been learned from the use of these early
compounds. What determines the potency of an inhibi-
tor in cells? What is required for a kinase inhibitor to be
selective, and how can this be measured? How is it
possible to validate pharmacological results? The aim
of this review is to suggest a framework for evaluating
and using kinase inhibitors with a focus on the use of
these reagents to explore signal transduction in cell-
culture-based model systems.
The Relationship between Potency
In Vitro and In Vivo
The potency of a kinase inhibitor for its target is typi-
cally expressed as an IC value—the concentration of50*Correspondence: shokat@cmp.ucsf.edudrug at which 50% of the kinase activity is inhibited.
Most kinase inhibitors are reversible and ATP competi-
tive, and for these reagents, the IC50 depends on the
intrinsic affinity of the inhibitor (the dissociation con-
stant, Ki) as well as the competition from ATP under the
specific assay conditions (the [ATP] and the KM, ATP).
These variables are related to each other by the Cheng-
Prusoff equation [10]:
IC50 = Ki(1 + [ATP] /KM, ATP)
This equation captures the fact that at low ATP con-
centrations, there is no significant competition from
substrate and the IC50 y Ki. As the ATP concentration
exceeds the KM, ATP, the IC50 increases at approxi-
mately the same rate (Figure 1A). Importantly, the IC50
does not plateau at a maximum value at high concen-
trations of ATP (in contrast to how an enzyme ap-
proaches Vmax as the [ATP] exceeds the KM, ATP).
For this reason, the potency of an inhibitor in cells
(where the ATP concentration is 1–5 mM [11, 12]) de-
pends critically on the KM, ATP of its target (Figure 1A).
An inhibitor that has similar Ki values against multiple
kinases will inhibit more potently in cells those kinases
that have a higher KM, ATP. We have assembled 238
published KM, ATP values for 111 protein and lipid ki-
nases (Table 1 and Figure S1 available with this article
online). The majority of these values are in the low- to
midmicromolar range, and for these targets, ATP-com-
petitive inhibitors should be active in cells at con-
centrations w10- to 100-fold above their Ki. There are
outliers, however, and these kinases will be more or
less difficult to target with ATP-competitive small
molecules. For example, several phosphatidylinositol
4-kinases and the related protein mTOR have millimolar
KM, ATP values [13–17], and we have argued that trends
in IC50 values for LY294002 analogs against phosphati-
dylinositol 3-kinases (PI3-Ks) can be explained largely
by differences in affinity for ATP [13].
An important caveat to the use of KM, ATP values is
that they are sensitive to the specific assay conditions
(such as choice of protein substrate [18] or counter ion
[19]). KM, ATP values for a single kinase measured under
different conditions generally show small variation (<5-
fold) (Figure S1) and, therefore, likely approximate the
true in vivo substrate affinity of these enzymes. How-
ever, for some kinases KM, ATP values are lower when
measured with protein substrates versus peptides [18]
or when manganese is used in place of magnesium
[20], and these factors must also be considered.
Most kinases are believed to interconvert between at
least two structural conformations, active and inactive,
and the phosphorylation of key residues can shift the
balance between these states (Figure 1B). These two
states are characterized by movements in conforma-
tionally mobile loops that border or block the ATP bind-
ing site (for example, the DFG motif). For this reason,
the KM, ATP may be significantly higher for the inactive
conformation than for the active conformation (Figure
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622Figure 1. The Cellular Potency of ATP-Competitive Kinase Inhibitors Depends on the KM, ATP
(A) Theoretical relationship between KM, ATP and cellular potency for an ATP-competitive inhibitor with a Ki of 10 nM.
(B) A simplified schematic depicting how different classes of kinase inhibitors may block kinase activity.
(C) Examples of kinases that show large differences in KM, ATP between two phosphorylated forms.1C). A growing number of kinase inhibitors selectively c
starget the inactive conformation [3, 21, 22], whereas
other compounds bind to both conformations with sim- r
milar affinity [23]. Inhibitors that bind to the inactive con-
formation will face weaker competition from cellular a
lATP, and this may enhance their activity in vivo. Indeed,
even though these compounds are ATP competitive, t
cthey may act primarily by shifting equilibria between
conformational states in a way that prevents kinase ac- p
ftivation, rather than by inhibiting kinase activity directly
(Figure 1B). For example, the p38α inhibitor SB203580, c
which binds to both conformations, has been proposed
to act in cells by stabilizing an inactive conforma- l
ftion that reduces the rate of p38α phosphorylation by
MAPKKs [23]. t
wBiochemical Activity Predicts Cellular Activity
Biochemical affinities are measured in vitro in order to o
fpredict concentration ranges at which kinase inhibitors
will be active in cells. To what extent does kinase inhibi- T
ttion in cells actually correlate with in vitro measure-
ments? To address this question, we analyzed pub- b
plished data for 13 classes of inhibitors that target three
different protein kinases: VEGF-R2, IKK-2, and Lck. Fig- i
aure 2 plots the relationship between biochemical Ki and
EC50 for these compounds. EC50 is defined as the con- c
pcentration of compound required to inhibit 50% of aellular phenotype (different colors represent different
tructural classes of inhibitors, whereas different shapes
epresent different cellular assays). Ki values were esti-
ated from in vitro IC50 values based on the reported
ssay conditions, and compounds were excluded that
acked potency in vitro (Ki > 1 M) or had no activity at
he highest concentration tested in cells (fewer than ten
ompounds). These values were then compared with
redictions based on the consensus KM, ATP reported
or these kinases assuming an intracellular ATP con-
entration of 2 mM (dotted lines).
Five chemotypes of VEGF-R2 inhibitors were ana-
yzed. There was a correlation between biochemical af-
inity and cellular potency for these molecules that ex-
ended across structural classes and among analogs
ithin a series. The EC50 for VEGF-R2 inhibitors was,
n average, 10-fold above the Ki, and most compounds
ell within a 5-fold window of this value (4- to 20-fold).
o what extent do these values match in vitro predic-
ions? The KM, ATP of the VEGF-R2 kinase domain has
een measured for the phosphorylated (active) and un-
hosphorylated (inactive) states by at least two laborator-
es, and the reported values are similar (130/900 M
nd 150/600 M [24, 25]). It is not known whether these
ompounds target the active or inactive state, so we
lotted the predicted relationship between EC and K50 i
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623Table 1. Selected KM, ATP Values for Protein and Lipid Kinases
Tyr Kinases Ser/Thr Kinases Lipid/PIK Kinases
c-Abl 12 Akt1 132 ATM (Mn) 29
v-Abl 18 Akt2 254 DNA-PK 228
Btk 29 Aurora 2 34 mTOR 1000
Csk 15 Cak1-Sc 5 p110α/p85α 62
EGFR 17 CaMKI 110 p110γ 7.5
EphA7 30 CaMKIIα 19 PI3KC2α 32
EphB3 (Mn) 2.7 CaMKIV 27 PI3KC2β 120
ErbB-2 27 CaMKKα 33 PI4KIIα 28
ErbB-4 37 CaMKKβ 33 PI4KIIIα 300
FAK (Mn) 4.3 CDK1/cyclin B 2.3 PI4KIIIβ 1000
FER 7.1 CDK2/cyclin A 23 PI(4)P(5)KI 25
c-Fgr 20 CDK2/cyclin E 3.6 PI(4)P(5)Kiα 27
FGFR 70 CDK4/cyclin D1 418 PI(4)P(5)Kiβ 33
Fyn 70 CDK4/cyclin D2 200 PI(4)P(5)Kiγ 39
IGFR 107 CDK5/p25 3.2 PI(5)P(4)KII 5
InsR 40 Chk1 1.4
ITK 36 Chk2 3.3
JAK1 15 CK1α 19
JAK3 6 CK1β 12
c-Kit 53.6 CK2α 13.9
Lck 10 CK2β 8.8
Lyn 35 CLK1 (Mn) 80
MER 40 CTR1-Ar (Mn) 9.1
MuSK 380 DAPK31 2.4
PDGFRβ 15 DMPK 2.3
c-Src 80 Erk2 140
v-Src-cat 12 GRK1 2
Syk 10 GRK2 60.8
c-Tak 3.3 GRK3 88.8
Tie-2 73.9 GRK5 23.8
TrkA (Mn) 9 GRK6 111
VEGF-R2 130 GSK3β 50.2
c-Yes (Mn) 16 IKK-1/IKK-2 13
Zap-70 3 IKK-2/IKK-2 18
IKK-i (Mn) 3.1
IRAK4 600
JNK2 39
JNK3α1 1.9
MAPKAPK2 43
MEK1 5.6
NIMA-As 69
p38α 25
p38γ 27
p90Rsk-B 35
PAK2 71
PhK 200
PKA-α 25
PKA-γ 9.1
PKC-α 24.3
PKC-βI 37.2
PKC-βII 20
PKC- 14.5
PKC-θ 49
PKG 5.1
PLK1 2.6
Raf-1 11.6
ROCK-I 4.5
ROCK-II 4.5
Sky1p-Sc 235
smMLCK 71
skMLCK 101
TBK-1 (Mn) 5.9
When multiple values were available for a single kinase, a consensus value was selected, with preference given to values measured with
magnesium, a protein substrate, and the active conformation of the kinase. A complete list, with phosphoacceptor data and references, is
available online as Figure S1. (Mn) indicates value was measured in the presence of manganese. Sc (Saccharomyces cerevisiae), Xe (Xenopus
laevis), Ar (Arabidopsis thaliana), Pb (Schizosaccharomyces pombe), Ca (Candida albicans), and As (Aspergillus nidulans).
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(Figure 2. Correlation between Ki and EC50 for a Sample of Inhibitors
of Three Protein Kinases s
b(A) VEGFR2: circles, VEGF-induced mitogenesis in HUVECs [119–nown to contribute to T cell signaling.
22]; squares, VEGF-induced p42/p44 MAPK phosphorylation in
UVECs.
B) IKK-2: circles, RANTES induction by TNFα in A549 cells [123–
25]; squares, production of TNFα by HUVECs stimulated with
PS [125].
C) Lck: circles, antibody-stimulated IL-2 secretion [126, 127];
quares, antibody-stimulated calcium release [127]; triangles, anti-
ody-stimulated T cell proliferation [128–130].or both conformations (dotted lines, Figure 2A). These
wo lines bracket most of the experimental values, sug-
esting that biochemical measurements predict the
ellular activity of VEGF-R2 inhibitors with good ac-
uracy.
We next analyzed data for inhibitors of IKK-2 (Figure
B). IκB kinases exhibit KM, ATP values in the submicro-
olar range [26–30]—some of the lowest values re-
orted for any protein kinase—suggesting that it may
e necessary to use IKK inhibitors at high concentra-
ions to achieve cellular activity (>1000-fold above Ki).
hree classes of IKK-2 inhibitors were compared, and
hese compounds exhibit a strong correlation between
iochemical Ki and EC50 across three orders of magni-
ude in inhibitor affinity (Figure 2B). Surprisingly the
C50 for IKK-2 inhibitors is, on average, only 44-fold
bove the Ki, corresponding to an effective KM, ATP of
6 M for this kinase. What accounts for this discrep-
ncy? One explanation is that the reported nanomolar
M, ATP values for IKK-2 (for example, 0.1, 0.14, 0.56,
.6, and 0.65 M [26–30]) were all measured under con-
itions that utilize manganese as a counterion. In the
resence of only magnesium, the physiological divalent
ation, the KM, ATP is 18 M [31]—a value more consis-
ent with the observed cellular activity of IKK-2 inhibi-
ors. This highlights the fact that biochemical affinities
easured with manganese are likely to be nonphysio-
ogical and may distort calculations of inhibitor po-
ency.
Figure 2C depicts data for five chemotypes of Lck
nhibitors, assayed according to their ability to block
alcium release, IL-2 secretion, or proliferation of T
ells. The cellular activity of these compounds falls into
wo classes. Calcium release is highly sensitive to Lck
nhibition (mean EC50y 11 Ki, corresponding to an ap-
arent KM, ATPy 300 M), whereas IL-2 production and
cell proliferation are much less sensitive, although al-
ost identical to each other (mean EC50y 440 Ki, cor-
esponding to apparent KM, ATP y 17 M). The latter
alue is close to the reported KM, ATP for Lck of 10 M
32], suggesting that the potencies against IL-2 prod-
ction and T cell proliferation are consistent with in vi-
ro measurements, whereas calcium release is unex-
ectedly sensitive. This may reflect different thresholds
or Lck activity for these two sets of processes and is
onsistent with the underlying differences in their kinet-
cs—calcium release occurs in seconds, whereas cy-
okine production and proliferation occur over days. In
eneral, these Lck inhibitors are also more varied in
heir cellular activity than IKK-2 or VEGF-R2 inhibitors.
n important component of this variation is likely to be
ifferences in the off-target activity of these inhibitors
gainst other Src family kinases, such as Fyn, that are
Review
625Sources of Deviation from Biochemical Predictions
The data from these three classes of inhibitors sug-
gests that to a first approximation, biochemical affini-
ties predict the cellular activity of kinase inhibitors re-
markably well. Still, it is clear that many kinase inhibitors
are more or less potent in cells than predicted by Ki
and KM, ATP, and it is certainly not possible to use these
values to calculate an exact EC50 value. For example,
the widely used PI3-K inhibitor LY294002 is consis-
tently w10-fold more potent in cells than biochemical
measurements would predict. What mechanisms can
account for discrepancies between inhibitor potency
in vitro and in cells?
Phosphatases Are Endogenous Kinase Inhibitors
Phosphatases reverse the action of kinases in vivo, and
this has the effect of systematically lowering the IC50
values for kinase inhibitors. This is because the net flux
of phosphorylated product in the cell is the difference
between the kinase and phosphatase activities. If the
kinase and phosphatase turn over their substrates at
similar rates, then inhibiting a small fraction of the ki-
nase activity can block the entire flux of phosphory-
lated product (Figure 3A). A prediction of this model is
that phosphatase inhibitors should decrease the po-
tency of kinase inhibitors, and, indeed, inhibitors of the
lipid phosphatase PTEN increase the cellular IC50 for
LY294002 by w5-fold [33]. Moreover, there is evidence
that some signaling pathways are controlled by high
levels of basal phosphatase activity. For example, treat-
ment of lymphocytes with tyrosine phosphatase inhibi-
tors can induce much higher phosphotyrosine levels
than any physiological stimulus [34], suggesting that in
these cells, the basal phosphatase activity is of the
same magnitude as the stimulated kinase activity. For
many signaling pathways, our understanding of the key
phosphatases, their direct substrates, and their modes
of regulation is limited compared to our understanding
of the corresponding kinases. Yet every phospho-regu-
lated step in signal transduction reflects a dynamic
equilibrium between these two activities, and the rela-
tive phosphatase activity in each step will influence its
sensitivity to small-molecule inhibition.
Kinase Reactions In Vivo Are Not Linear
IC50 values are measured in vitro in the presence of a
large excess of phosphoacceptor substrate, such that
the substrate concentration does not change signifi-
cantly during the course of the assay (that is, only initial
rates are measured). Under these conditions, the rela-
tionship between the concentration of active kinase
(the fraction of the total kinase not inhibited by drug)
and the concentration of phosphorylated substrate is
linear (Figure 3B, black dashed line). This is not neces-
sarily the case in the cell, where a kinase may phos-
phorylate a large fraction of its protein substrate; the
fact that it is often possible to monitor protein phos-
phorylation by observing a molecular weight shift via
SDS-PAGE is evidence that phosphorylation can occur
at high stoichiometry in cells. Under these conditions,
where phosphoacceptor substrate is significantly con-
sumed, the concentration of active kinase and its phos-
phorylated substrate are related by a hyperbolic curve
indicative of Michaelis-Menten kinetics (Figure 3B, red).
In other cases, Ferrell and coworkers have shown that
kinase-mediated signaling pathways, such as the MAPkinase cascade, can behave cooperatively, such that
the concentration of active kinase and its phosphory-
lated substrate are related by a sigmoidal rather than
hyperbolic curve [35, 36] (so-called ultrasensitivity) (Fig-
ure 3B, blue). This ultrasensitivity has been attributed
to a number of features, including multisite phosphory-
lation of a single substrate, the activity of a kinase at
multiple steps within a pathway, or the presence of sev-
eral kinases arranged in a linear cascade.
The precise nature of the relationship between kinase
activity and output for any given signaling pathway has
implications for the sensitivity of kinases to small-mole-
cule inhibition. Under Michaelis-Menten conditions, the
biochemical IC50 (the concentration of drug at which
half the kinase active sites are occupied by inhibitor in
cells) is always lower than the EC50 (the concentration
of drug at which half the total kinase activity is inhibited
in cells) (Figure 3C). The magnitude of this effect can
be large at very high stoichiometries of substrate con-
sumption and tends to make kinase inhibitors appear
less potent in cell culture than would be predicted by
in vitro measurements. As the fraction of phosphoac-
ceptor substrate that is consumed decreases (because
of a weaker stimulus, a shorter time point, or a more
abundant substrate), the hyperbolic Michaelis-Menten
curve approaches in the limit the linear conditions ob-
served in vitro, in which substrate is essentially unlim-
ited and the biochemical IC50 and EC50 are identical.
Ultrasensitive behavior can make a kinase inhibitor
seem more or less potent in cells, depending on the
fraction of substrate that is consumed under the given
assay conditions. At low substrate consumption, more
than 50% of the net kinase activity can be inhibited by
occupying less than 50% of the kinase active sites with
inhibitor (Figure 3C). At high substrate consumption,
the ultrasensitive response converges to the behavior
of normal Michaelis-Menten kinetics.
Huang et al. have experimentally confirmed that the
relationship between MAPKKK activity and the activity
of its downstream effectors (MAPKK and MAPK) in
Xenopus oocyte extracts exhibits ultrasensitivity, and
this can be described by Hill coefficients of approxi-
mately two and five, respectively [36]. A consequence
of this fact is that a MAPKKK inhibitor that blocks 50%
of MAPKK activation will inhibit less than 50% of MAPK
activation, even though these enzymes are directly
connected in a linear signaling cascade (Figure 3D). Al-
though most signaling pathways have not been charac-
terized at this level of detail, many common mecha-
nisms of signal transduction contain features that may
introduce cooperativity and thereby perturb inhibitor
sensitivity. For example, PI3-kinase activates the down-
stream kinase Akt by recruiting it and its upstream ki-
nase PDK1 to the plasma membrane (Figure 3D). The
quantitative relationship between PI3-K activity (PIP3
generation) and Akt phosphorylation by PDK1 is un-
known, but the simplest model is that Akt phosphoryla-
tion is a bimolecular reaction between Akt and PDK1,
and, therefore, the rate is dependent on the concentra-
tion of each at the membrane (v[pAkt] = k1[Akt][PDK1]).
If the membrane concentration of each protein is pro-
portional is to the concentration of PIP3 ([Akt], [PDK1] f
[PIP3]), then the rate of Akt phosphorylation should in-
crease according to the square of the PIP concentra-3
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626Figure 3. Factors that Can Influence Inhibitor Sensitivity in Cells
(A) Phosphatase activity can lower IC50 values for kinase inhibitors. In the absence of phosphatase activity, the IC50 for an inhibitor is the
concentration at which half the kinase activity is inhibited (here, 600/2 = 300/s). In the presence of a fixed phosphatase activity of 400/s (red
line), the net flux of kinase activity is reduced to 200/s. Therefore, inhibiting only 100/600 y 16% of the direct kinase activity will block 100/
200y 50% of the net flux of kinase activity. This model may be realistic for early time points, when the phosphatase activity is constant and
independent of the kinase activity.
(B) The concentration of phosphorylated substrate ([p-substrate]) can have differential dependence on the concentration of active kinase
([active kinase]) depending on whether the activity obeys linear (dashed), Michaelis-Menton (red), or ultrasensitive (blue) kinetics [35]. Increas-
ing the strength of the cellular stimulus or the length of time will shift the reaction to the right along these curves, whereas increasing the
concentration of inhibitor or the stoichiometry of substrate will shift the reaction to the left.
(C) Detailed analysis of the effect that Michaelis-Menton or ultrasensitive kinetics can have on kinase sensitivity to inhibitors. For a linear
response, the concentration of drug necessary to reduce the [p-substrate] by 50% corresponds to a 50% reduction in [active kinase] (that
is, 50% of the kinase active sites are bound to drug). For Michaelis-Menton and ultrasensitive responses, reducing the [active kinase] by
more or less than 50% is necessary to reduce the [p-substrate] by 50%.
(D) Schematic diagram of signaling in MAP kinase, PI3-K, and receptor tyrosine kinase (RTK) pathways.tion (v[pAkt] = kobs[PIP3]2). Under conditions of low c
fsubstrate consumption in which this model may be
realistic, PI3-K inhibitors should block Akt phosphory- a
rlation more potently than they block PI3-K activity di-
rectly (for example, inhibition of 50% of PI3-K activity t
tshould reduce phosphorylated Akt by 75%). A similar
model would apply to a receptor tyrosine kinase, whose e
dkinase activity both recruits its substrates via SH2 do-
main-phosphotyrosine interactions and subsequently a
pactivates them by direct phosphorylation (Figure 3D). It
will be interesting to test these models experimentally
ain an effort to delineate the quantitative relationship be-
tween kinase inhibition and signaling output for dif- (
fferent pathways.
Bioavailability of Kinase Inhibitors t
cKinase inhibitors must enter the cell in order to inhibittheir targets. The bioavailability of a kinase inhibitor inell culture depends primarily on two factors. (1) How
ast does the intracellular inhibitor concentration reach
steady state? (2) At the steady state, what are the
elative concentrations of inhibitor inside and outside
he cell? These questions depend largely on the magni-
ude of two rates: the rate at which the compound
nters the cell by diffusion down the concentration gra-
ient that exists across the membrane (the cell perme-
bility) and the rate at which the compound is actively
umped out of the cell by efflux pumps.
For a given concentration gradient, the cell perme-
bility of a compound is proportional to its lipophilicity
more lipophilic compounds will partition more readily
rom water into a membrane) and inversely proportional
o its size. For this reason, molecules that are highly
harged, have too many hydrogen bond donors and ac-ceptors, or are very large cross cellular membranes
Review
627slowly. However, molecules that are extremely hy-
drophobic also have poor effective permeability either
because they lack aqueous solubility, fail to partition
out of the plasma membrane, or bind tightly to serum
proteins. “Drug-like” kinase inhibitors tend to lack
these structural defects, and these molecules often
have very high rates of cell permeation. For example,
levels of PIP3 in insulin-stimulated 3T3-L1 cells sharply
decline within w1 min of LY294002 addition [37]. Actin
rearrangements can be observed in T cells within 3–5
min of addition of the Lck inhibitor PP2 at a low dose
(20 nM) [38]. Because it is customary to preincubate
kinase inhibitors for 30–90 min prior to stimulation of
the cell, it is safe to assume that most drug-like kinase
inhibitors approach their steady state within the experi-
mental time scale.
Inhibitors are also pumped out of the cell by drug
efflux pumps. The rate of efflux depends on the intra-
cellular inhibitor concentration, the KM of a specific in-
hibitor for a given pump, and the overall level of pump
activity. In some cases, the activity of efflux pumps can
significantly lower the steady-state concentration of a
drug. S. cerevisiae, for example, is resistant to many
small-molecule inhibitors that are active in mammalian
cells. Deletion of specific drug pumps renders yeast
sensitive to most of these same compounds [39]. This
is also the case for some tumor cells that overexpress
transporters such as p-glycoprotein; expression of
these transporters has been shown to reduce the
steady-state intracellular drug concentration by up to
50-fold [40]. By contrast, most mammalian cells in cul-
ture appear to have less efflux activity.
There is little published data that directly compares
the bioavailability of different classes of kinase inhibi-
tors in cell culture (bioavailability in animals is beyond
the scope of this review). For drug-like kinase inhibitors
with characteristically high rates of cell permeation, it
seems likely that differences in steady-state intracellu-
lar drug concentration are the major source of experi-
mental variation because of bioavailability. If this were
not the case, then the potency of kinase inhibitors in
cells would be highly sensitive to the length of preincu-
bation; but this is not generally observed. An upper limit
to the differences in steady-state bioavailability can be
estimated indirectly by analyzing the scatter in plots
such as Figure 2. Part of the deviation of this data from
a straight line reflects differences in bioavailability
across compounds (other factors include experimental
error in measuring the in vitro and cellular IC50 values as
well as differences in how these assays are conducted
across different laboratories). For most of the com-
pounds analyzed here, the cellular activity deviates
from the mean within a 10-fold window for any given
phenotypic endpoint. This represents an upper bound
on the typical differences in bioavailability for potent,
drug-like kinase inhibitors. Given that there are other
significant sources of uncontrolled error in this analysis,
this suggests that differences in bioavailability for ki-
nase inhibitors in cell culture may be smaller than gen-
erally believed.
Kinases Are Low-Abundance Proteins
The lowest IC50 value that can be measured in vitro is
determined by the concentration of kinase used in the
assay. An IC value cannot be lower than one-half the50
concentration of kinase, because it is not possible toinactivate more than one kinase per molecule of drug
(assuming a normal reversible binding mechanism). By
extending this reasoning, it is sometimes argued that
the potency of an inhibitor in cells depends on the intra-
cellular concentration of its kinase target. A very abun-
dant kinase will titrate a small molecule inhibitor out of
solution such that the concentration of the kinase
places a lower limit on the cellular IC50 for the inhibitor.
In most experimental settings, this reasoning is incor-
rect: the potency of a kinase inhibitor in cells should be
independent of the concentration of its target (here,
the concentration of kinase is distinguished from the
amount of kinase activity). This is because kinase inhib-
itors are typically supplied in a large reservoir that can
exchange matter with the cell, and the presence of a
high affinity receptor within the cell will increase the
steady-state intracellular drug concentration. For ex-
ample, for most experiments in tissue culture, kinase
inhibitors are added to the media and enter the cell
through passive diffusion. Standard conditions for the
growth of tissue culture cells—106 cells growing in a 10
cm dish bathed in 10 ml of media—correspond to a
volume of cell culture media 10,000-fold greater than
the volume of cells. In this regime, no change in the
concentration of inhibitor within the cell can signifi-
cantly alter the concentration of inhibitor in the media.
For a potent inhibitor of an abundant kinase (Ki << [ki-
nase]), the binding of the inhibitor to the kinase will
therefore increase the total intracellular concentration
of inhibitor because the driving force for diffusion
across the membrane is primarily the concentration
gradient of unbound inhibitor.
Natural variation in the expression levels of kinases
can affect inhibitor sensitivity indirectly by changing the
level of total kinase activity and, thereby, the number of
turnovers needed to consume substrate or overcome a
phenotypic threshold. For example, cell lines that over-
express Bcr-Abl can be made 3-fold more sensitive to
Imatinib by reduction of Bcr-Abl levels via RNAi [41].
Limited data is available on the absolute expression
level of most proteins in mammalian cells, but the ex-
pression of 80% of the predicted genes in yeast has
been measured with an epitope-tag library [42]. This
data set includes absolute expression levels for 84 of
the 116 protein kinases predicted by the yeast genome,
and we converted these values to protein concentra-
tions by assuming a volume of 70 m3 for haploid
S. cerevisiae [43] (Figure 4A). By this calculation, 63%
of protein kinases are expressed at a concentration be-
tween 1 and 50 nM, and only 11 kinases (13%) are ex-
pressed at higher than 150 nM, with a maximum con-
centration of w240 nM. By comparison, the median
protein concentration in S. cerevisiae is w54 nM, and
the most abundant protein is expressed at w38 M.
These calculations do not include values for the 38%
of kinases for which expression data is unavailable, al-
though the absence of data likely reflects the extremely
low abundance of many of these proteins. Available
data from mammalian cells and Xenopus oocytes
is generally consistent with these concentrations, al-
though some highly abundant kinases such as MAPKs
and CDKs can be expressed as high as 1–2 M [35, 44,
45]. These values provide some insight into the abun-
dance of specific kinases within the protein-kinase su-
perfamily and relative to other cellular proteins; how-
Chemistry & Biology
628Figure 4. Biochemical Properties of Kinases and Kinase Inhibitors
(A) The fraction of kinases that are expressed at less than a given cellular concentration in S. cerevisiae.
(B) The 11 most highly expressed protein kinases in S. cerevisiae.
(C) Comparison of drug-like properties of Imatinib and a curcumin derivative.
(D) Proposed general guidelines for estimating the likelihood of off-target (nonkinase) effects at different concentration ranges of inhibitor
applied to cells.ever, it remains necessary to empirically determine the
lrelationship between expression levels and inhibitor
sensitivity for any specific kinase. s
nThe Distribution of Pharmacological Variation
We have highlighted some of the reasons why the po- a
mtency of kinase inhibitors in cells may deviate from bio-
chemical predictions. This is not to suggest it is pos- p
ssible to predict these deviations in any specific case.
The important fact is that kinase inhibitors have been s
successfully used to dissect signaling pathways, and e
this implies that the sources of variation in inhibitor po- t
tency must be small in magnitude and poorly corre- i
lated, such that their net effect causes modest overall t
deviations from in vitro predictions. This result was not r
guaranteed. Indeed, the effectiveness of kinase inhibi- c
tors in cells is entirely contingent on the fact that evolu- s
tion has tuned the biochemical activities of kinases to
phosphorylate a significant fraction of their substrates,
Sbut not much more, during the time course of an ordi-
onary stimulus. If kinases were endowed with significant
Sexcess catalytic capacity—for example, 100-fold more
Mactivity than needed to phosphorylate 90% of their
cavailable substrate—then it would be, for all practicalpurposes, impossible to make a kinase inhibitor.The identification of different sources of pharmaco-
ogical variation has implications for kinase-inhibitor
electivity, even if it is not possible to predict the mag-
itude of these effects. Highly related kinases (for ex-
mple, isoforms within a family) are more likely to share
any sources of variation—such as a common phos-
hatase, similar levels of specific activity relative to
ubstrate abundance, and downstream effectors with
imilar kinetics and thresholds of activation. The pres-
nce of these shared signaling components reduces
he number of potential sources of deviation for the
n vivo activity of different small-molecule inhibitors of
hese targets. This argues, counterintuitively, that closely
elated kinases should be easier to selectively inhibit in
ells, given a fixed level of biochemical selectivity of a
mall-molecule inhibitor.
tructural and Biochemical Features
f Selective Inhibitors
elective Inhibitors Are Drug-like Molecules
ost selective kinase inhibitors are drug-like mole-
ules. Even though a kinase inhibitor can be a useful
research tool without the functional properties of a drug
Review
629(for example, oral bioavailability), drug-like compounds
strike an appropriate balance between aqueous solubil-
ity and cell permeability [46], both of which are nec-
essary for activity in cells. Furthermore, nondrug-like
molecules often have structural properties that com-
promise their selectivity. In the words of Lipinski and
Hopkins, “chemical features associated with failure in
drug discovery tend to cause compounds to have ‘pro-
miscuous’ effects in biological systems” [47].
Several approaches have been advanced to define
“drug likeness” by identifying the chemical features
shared by orally active drugs. Lipinski’s rule of five
identifies upper limits on the molecular weight (<500
Da), hydrophobicity (ClogP % 5), and the number of
hydrogen bond donors (% five) and acceptors (% ten)
that most drugs possess [48]. An alternative proposal
by Veber has emphasized the fact that oral absorption
is favored by low polar surface area (less than 140 Å2)
and decreased ligand flexibility (ten or fewer freely ro-
tatable bonds) [49].
Beyond specific drug-like properties, selective ki-
nase inhibitors are almost always heterocycles, rather
than peptides, lipids, or other substrate analogs (for ex-
ample, see Figure 4C). They are typically entropically
constrained, with four or fewer freely rotatable bonds
connecting any two ring systems. Most importantly,
they exhibit dramatic structure-activity relationships
(SARs). For example, almost all ATP-competitive kinase
inhibitors satisfy at least one of the hydrogen bonds
that is made between the adenine ring of ATP and the
kinase [50]. Substitution of this hydrogen bonding atom
can result in a w1000-fold loss in affinity.
Many nonspecific kinase inhibitors share a distinct
set of structural features (Figure 4C). Promiscuous
compounds often have dye-like structures—flat, highly
conjugated polyaromatic systems. These compounds
tend to be hydrophobic, bind proteins nonspecifically,
and aggregate at high concentrations [51]. Certain
chemical moieties, such as catechols, are commonly
found in low-specificity inhibitors such as many fla-
vones and tyrphostins. Catechols have been shown to
undergo cellular oxidation to generate more reactive
species that probably account for some of the in vivo
activity of these molecules [52, 53]. This oxidation can
also be catalyzed in vitro by manganese, a common
component of many kinase assay buffers, and this has
been shown to contribute to the biochemical potency
of catechols from four different scaffold classes [54].
Another feature common to low specificity kinase inhib-
itors is a plane or axis of symmetry. Although symmetric
molecules are prevalent in screening libraries, kinase
active sites are asymmetric. For this reason, symmetry
is usually an indication that a molecule has not un-
dergone target-directed chemical optimization.
Shoichet and coworkers have defined a mechanism
for nonspecific inhibition in vitro that involves the for-
mation of submicrometer aggregates [51, 55]. This ag-
gregate formation is time dependent, sensitive to pro-
tein concentration, and reversible by detergents and
may form the basis for the in vitro activity of low-speci-
ficity kinase inhibitors such as quercetin and rottlerin
[55]. However, it is important to emphasize that this
type of aggregation has been observed only at micro-
molar concentrations. For an ATP-competitive kinaseinhibitor, a micromolar Ki alone is compelling evidence
that the compound is not selective.
Kinase inhibitors containing electrophiles, such as
Michael acceptors or α-haloketones, generally exhibit
poor stability and increased off-target effects. For ex-
ample, the electrophilic natural product wortmannin
has a half-life in tissue culture media of w10 min [56],
whereas vinyl nitriles, such as those found in U0126,
can undergo rearrangements on storage in DMSO [57].
Although electrophiles are frequent hits from screening
libraries, it is generally not possible to optimize these
leads because their activity is based on more chemical
reactivity rather than target-specific contacts [58]. None-
theless, recent examples of selective electrophilic inhib-
itors have been reported [59] (M. Cohen et al., submit-
ted). An essential feature of these compounds is that
they possess a core scaffold that binds reversibly to
the kinase with moderately high affinity (Ki < 1 M). This
scaffold then positions a relatively deactivated electro-
phile in proximity to a nucleophilic residue found in a
subset of targets in the kinase superfamily. Absent this
tight binding, reversible core structure, it is not possible
to attain a high degree of selectivity with an irrevers-
ible inhibitor.
Inhibitor Selectivity Is Measured In Vitro
The target selectivity of a kinase inhibitor is typically
measured by profiling its activity against a panel of ki-
nases in vitro. Kinases most closely related in primary
sequence are most likely to share inhibitor sensitivity
[60], and these are the most important targets to test.
In some cases, impressive selectivity against a panel
of closely related kinases can suggest a high degree
of selectivity against the remainder of the kinome. For
example, BAY 61-3606 inhibits Syk with a Ki of 7.5 nM
and exhibits R1000-fold selectivity against the related
tyrosine kinases Src, Fyn, Lck, Btk, and Itk, suggestive
of a high degree of selectivity against less similar ki-
nases [61]. In most cases, it is important to sample a
broad range of kinases from different kinase subfamil-
ies. Two valuable studies have profiled many of the
most commonly used kinase inhibitors against 28 pro-
tein kinases in this way [62, 63].
The limitation of this approach is that even the largest
kinase panels test only w20% of the kinome and,
therefore, may miss important targets (although for
smaller families, such as the lipid kinases, near-exhaus-
tive coverage is feasible [13]). Despite this limitation,
specific features beyond sequence homology have
been identified that predict kinase inhibition, and these
can be used to select the best targets for testing. For
example, the size of a single amino acid in the ATP
binding pocket—termed the gatekeeper residue—has
been shown to be a critical determinant of inhibitor
sensitivity [64, 65]. Kinases with a threonine at this po-
sition are sensitive to a range of inhibitors, whereas
those with a larger residue are broadly resistant. Ap-
proximately 50% of tyrosine kinases contain a threo-
nine gatekeeper, compared to 10% of serine-threonine
kinases. For this reason, serine-threonine kinases that
possess a threonine gatekeeper (for example, Raf and
p38α) are often sensitive to tyrosine kinase inhibitors,
and vice versa [64, 66]. In the same way, certain pairs
of kinases are known to exhibit similar pharmacological
profiles (so-called SAR homology [67]). For example,
GSK3β inhibitors often inhibit CDKs and TGFβ-R inhibi-
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ikinases possess limited sequence homology. Likewise,
there is growing appreciation that PI3-K inhibitors tend t
to inhibit the related protein kinase DNA-PK much more
frequently than other PI3-K-related kinases (PIKKs) l
tsuch as ATM and ATR [13, 68].
Affinity chromatography offers a way of identifying o
tinhibitor targets that is complementary to in vitro mea-
surements. In this approach, the inhibitor is linked to m
wsolid support and used to enrich for cellular binding
proteins, which are then identified by mass spectrome- p
8try. This approach has been successfully used to iden-
tify unexpected cellular targets of kinase inhibitors l
tsuch as SB203580, which was shown to inhibit RICK
more potently than its known target, p38α [66]. Im- t
cprovements in methodology have made this an increas-
ingly viable strategy for target identification; immobi- p
glized pyrido[2,3-d]pyrimidines have recently been used
to enrich for over 20 kinases from cell lysates [69]. A a
alimitation of affinity chromatography, however, is that it
is biased toward more abundant proteins. Four kinase A
Mfamilies—CDKs [70–74], CK1 isoforms [68, 70], MAP ki-
nases [66, 70–72, 75], and GSK3β [66, 71, 74, 76]— f
haccount for a disproportionate fraction of the kinase
targets that have been identified by affinity-based ap- w
pproaches. This reflects, in part, the relative cellular
abundance of these proteins, each of which is an or- H
ttholog of one of the most highly expressed kinases in
yeast (Figure 4B). Consistent with this view, subsequent a
Bbiochemical analysis often reveals that the bait com-
pound inhibits these kinases weakly in solution [66, 70, A
t72, 74, 75]. For this reason, affinity chromatography
may identify new targets of an inhibitor but does not b
pvalidate inhibitor specificity.
Selectivity Depends on Potency c
iThere are on the order of 20,000 unique protein recep-
tors in the cell, and it is impossible to test any signifi- i
cant fraction of these targets. At high compound concen-
trations, it becomes increasingly likely that an inhibitor c
pwill bind to these off-target sites. For this reason, the
practical selectivity of a compound depends on its po- m
ptency—more potent compounds are more selective be-
cause they can be used at a lower dose. This is also p
Ttrue within the protein-kinase family, in which there is a
strong correlation between inhibitor potency and selec- m
itivity [67]. An important corollary of this fact is that
there is a minimum threshold of potency without which p
ma molecule cannot be selective, irrespective of any
in vitro data. t
mThe PI3-K inhibitors LY294002 and wortmannin il-
lustrate this point. Both have been extensively profiled n
bin vitro and show similar specificity profiles at their re-
spective concentration ranges. These two compounds m
tinhibit the class I PI3K’s most potently, with mixed ac-
tivity against the other PI3-K family members [13] and s
man off-target activity against two protein kinases: CK2
(LY294002), sMLCK (wortmannin), and PLK1 (both) [77]. w
tYet these compounds are not equally selective in cells
because wortmannin is used at 1000-fold lower con-
ncentrations. Several new targets of LY294002 have
recently been identified, including calcium channels, T
ppotassium channels, phosphodiesterases, and the es-
trogen receptor [78–81], and these are inhibited in the R
wconcentration range that is commonly used to inhibitI3-Ks. A similar spectrum of targets has not been
dentified for wortmannin at the low nanomolar concen-
rations at which it inhibits PI3-Ks.
We have proposed guidelines for estimating the like-
ihood of off-target effects across different concentra-
ion ranges (Figure 4D). This estimation is based in part
n the observation that the fraction of small molecules
hat bind to a protein in vitro is generally low at nano-
olar concentrations but increases dramatically above
10 M. This is structure dependent—certain com-
ound classes are more promiscuous than others [82,
3]. Most selective kinase inhibitors have low nanomo-
ar Ki values and, so, are applied to cells at concentra-
ions less than 10 M, reducing the likelihood of off-
arget effects. Unfortunately, many of earliest and most
ommonly used kinase inhibitors are significantly less
otent, and conclusions based on the use of these rea-
ents are suspect. Compounds used at concentrations
bove 100 M (for example, the PIKK inhibitor caffeine)
re unlikely to have any significant selectivity.
New Generation of Allosteric Kinase Inhibitors
ost kinase inhibitors are ATP competitive, which re-
lects the fact that ATP binding pocket presents a large
ydrophobic surface that can bind small molecules
ith high affinity. It is much more difficult to find com-
ounds that bind to other regions of protein kinases.
owever, in some cases, it has been possible to iden-
ify such molecules, and, once identified, they possess
dvantages over their ATP-competitive counterparts.
ecause these inhibitors do not compete with cellular
TP, they can typically be used at concentrations closer
o their biochemical Ki. Also, residues outside the ATP
inding pocket tend to be less conserved, opening the
ossibility for greater selectivity. In certain cases non-
ompetitive inhibitors can be substrate selective, inhib-
ting the activity of a kinase against only a subset of
ts targets.
The first noncompetitive kinase inhibitor to be dis-
overed was rapamycin, a cyclic macrolide natural
roduct that inhibits the protein kinase mTOR. Rapa-
ycin acts by binding to the ubiquitously expressed
rotein FKBP [84], and it is this rapamycin-FKBP com-
lex that binds to the FRB domain of mTOR [85, 86].
he FRB domain is N terminal to the mTOR kinase do-
ain, and it is not understood how this binding event
nhibits mTOR activity [87]. In cells, mTOR resides as
art of two large (w2 MDa) protein complexes, termed
TORC1 and mTORC2 [88, 89]. Remarkably, only
he first of these complexes is rapamycin sensitive.
TORC1 signals to increase translation in response to
utrients and growth factors, and this complex can
e isolated by immobilized rapamycin-FKBP [88, 89].
TORC2 signals to the actin cytoskeleton in response
o the same stimuli, and this complex is rapamycin in-
ensitive [88, 89]. Potent, ATP-competitive inhibitors of
TOR have not been reported, but such compounds
ill be an important tool for elucidating signaling
hrough mTORC2.
The MEK1 inhibitor PD098059 was the first synthetic
oncompetitive kinase inhibitor to be described [90].
his compound acts by binding to inactive MEK1 and
reventing its phosphorylation by the upstream kinase
af [91]. The key to the discovery of this compound
as the use of a biochemical screen based on reconsti-
Review
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screen utilized a low activity form of MEK1, it was pos-
sible to identify a noncompetitive inhibitor of MEK1 ac-
tivation [93]. Several subsequent allosteric inhibitors of
MEK1 and MEK2 have been described, including U0126
and PD184352 [92, 93]. The recent crystal structural of
a PD184352 analog in complex with MEK1 confirms
that these compounds bind to a site adjacent to but
not overlapping with the ATP binding pocket [94]. More-
over, the low degree of sequence conservation in this
region of the kinase explains the high selectivity of
these compounds [94].
For many years, the MEK inhibitors were an isolated
example of potent, synthetic kinase inhibitors that bind
to an allosteric site. Recently, however, several new al-
losteric inhibitors have been described. Scientists from
Merck have reported several classes of compounds, in-
cluding a series of pyrazinones (Figure 5), which are
allosteric inhibitors of Akt. These compounds are non-
competitive with ATP, show selectivity between the iso-
forms Akt1 and Akt2, and bind to a region that includes
the Akt-PH domain [4]. BMS-345541 has been reported
as an allosteric inhibitor of IKK-2 that displays potent
activity in an animal model of inflammation [5] (Figure
5). Several classes of nanomolar noncompetitive inhibi-
tors of p38α have recently been described, along with
extensive structural and biophysical characterization of
their binding sites [3, 95]. Remarkably, at least one of
these compounds is substrate selective, blocking p38α
phosphorylation of MAPKAP2 but not ATF-2 [95].
The Intersection of Pharmacology and Genetics
Target Validation with Resistant
and Analog-Sensitive Alleles
The classic way to confirm the phenotypically relevant
target of a small molecule is to use a mutant allele of
the kinase that has altered sensitivity to the inhibitor.
For example, the TOR proteins were identified as the
target of rapamycin through a screen for yeast mutants
resistant to rapamycin [85]. Ecoptic expression of in-
hibitor-resistant allele of p38α has been used to confirm
that p38α is the target of SB203580-mediated blockade
of certain inflammatory responses [96]. Most recently,
the identification of Bcr-Abl mutations that block Imat-
inib binding from CML patients refractory to Imatinib
treatment confirms that Bcr-Abl is a clinically relevant
target of this molecule [97].
A related approach is to use a kinase allele that is
sensitive to a small molecule inhibitor that does not in-
hibit any wild-type kinase. For protein kinases, muta-
tion of the gatekeeper residue to alanine or glycine can
generate such analog-sensitive (as) kinase alleles [98].
By replacing the endogenous copy of the kinase with
the as allele, the effects of inhibiting that kinase in a
model system can be studied with a highly specific in-
hibitor. A key feature of this approach is that it is pos-
sible to directly confirm that the phenotype is due to
inhibition of the as kinase by performing a control ex-
periment in which cells expressing the wild-type kinase
are treated with the same inhibitor.
Resistant and analog-sensitive alleles are comple-
mentary approaches to studying kinase function. The
former asks whether inhibition of a kinase is necessaryfor a phenotype, whereas the latter asks if it is suffi-
cient. Resistance mutations are typically used in the
last stages of target validation, after an inhibitor, phe-
notype, and putative kinase target have been identified.
By contrast, analog-sensitive alleles can be used in a
discovery setting to identify new biological processes
that are sensitive to inhibition of a specific kinase.
Knockouts and Inhibitors Can Yield
Different Phenotypes
Genetic techniques such as RNAi and knockout ani-
mals offer an alternative to small-molecule inhibitors to
study kinase function. RNAi in particular has great util-
ity because it can be used to rapidly inactivate specific
genes in cell culture. It is frequently proposed that RNAi
might be used to validate targets for small molecule
inhibition or confirm results from pharmacological ex-
periments. Is this reasonable? Setting aside the fact
that RNAi is itself a pharmacological intervention—with
its own dose-dependent specificity limitations [99]—
this belief reflects an underlying assumption that ge-
netic knockdown of a kinase should phenocopy small-
molecule inhibition [100].
There are many reasons to conclude this is incorrect
[101]. Most kinases are multidomain proteins, and these
other domains often possess kinase-independent func-
tions [102, 103]. In some cases, the kinase domain itself
has noncatalytic activity [104, 105]. It would be difficult
to construct an accurate genetic model for an inhibitor
such as rapamycin, which blocks a subset of mTOR’s
cellular functions by a complex mechanism, yet this
compound was the first small-molecule kinase inhibi-
tor approved for clinical use [106]. Most importantly,
knockout mice for many kinases have surprisingly
few detectable phenotypes [107]—indicating that other
kinases may be able to mask the function of the
knocked-out gene through compensation [108, 109].
Chemical inhibition of as-kinase alleles makes it pos-
sible to directly compare phenotypes of chemical and
genetic kinase knockouts with inhibitors that have vali-
dated “single-target” specificity. These experiments in-
dicate that small-molecule kinase inhibitors rarely, if
ever, precisely phenocopy the corresponding gene
knockout (Table 2). The knockout frequently elicits phe-
notypes not observed with the inhibitor [110, 111] (likely
because of noncatalytic scaffolding functions of the ki-
nase); the inhibitor induces phenotypes not observed
in the knockout [98, 112] (likely because of compensa-
tion for the knockout by a homologous kinase); and, in
at least one case, the inhibitor elicits the exact opposite
phenotype as the knockout [104] (because of a noncat-
alytic, allosteric role of the kinase domain in signal
propagation). These observations mirror studies com-
paring knockout mice and with mice expressing a ki-
nase-dead allele (which better mimics the effects of a
small molecule inhibitor). In many cases, the pheno-
types are quite different [103, 113–115].
An additional layer of complexity arises from the fact
that very few inhibitors target a single protein kinase,
and the biological activity of these molecules may de-
pend on a complex balance of inhibition of multiple
targets. For example, CML, a disease characterized by
the chromosomal translocation that generates the Bcr-
Abl oncogene, may define the simplest link between
genotype and kinase-inhibition phenotype. Yet it is
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633Table 2. Examples of Chemical and Genetic Kinase Knockouts that Produce Different Phenotypes
Kinase Knockout Phenotype Inhibition Phenotype Proposed Explanation
CDC28 CDC28-ts allele arrests in G1 at Inhibition of the CDC28-as1 allele induces The mitotic checkpoint is more sensitive
restrictive temperature arrest at G2/M at low doses and G1 at to CDK activity than the G1 checkpoint
high doses
Ire1 Ire1 or Ire1-kd cells have defective Inhibition of an Ire1-as allele that also An ATP competitive inhibitor of Ire1
unfolded-protein response (UPR) contains a kd mutation permits the UPR permits activation of its RNAse domain
during the UPR
Apg1 Apg1 cells are defective in Inhibition of Apg1-as allele or expression Cvt requires the catalytic activity of
cytoplasm to vacuole targeting of Apg1-kd blocks Cvt but not Apg1, whereas autophagy requires a
(Cvt) as well as autophagy autophagy scaffolding function
Cla4 Cla4 cells have defective septin Inhibition of Cla4-as allele has no effect Septin localization may depend on a
localization to the bud neck on septin localization scaffolding function of Cla4
Elm1 Elm1 cells undergo G2/M delay Inhibition of elm1-as allele results in G1 Compensation for G1 defect in elm1
delay in bud emergence and Cln2 cells by accummulation of suppressors
synthesis, as well as G2/M defect during culture
p110γ P110γ−/− mice show increased p110γ-kd mice have normal cardiac p110γ interacts with PDE3B and
cardiac contractility and tissue function regulates heart contractility
damage independent of kinase activity
References: CDC28 [98], Ire1 [104], Apg1 [110], Cla4 [111], Elm1 [112], p110γ [103, 113].clear that Imatinib’s activity requires more than Bcr-Abl
inhibition in some settings. The Imatinib sensitivity of
murine myeloid leukemia cells that express both Bcr-
Abl and c-Kit is dependent on Imatinib’s ability to inhibit
c-Kit [116]. Inhibition of Bcr-Abl is necessary but not
sufficient to induce apoptosis in these cells. In this
case, the Imatinib activity against c-Kit was an unin-
tended by-product of the drug-discovery process, and
this sort of multitargeted activity would be challenging
to engineer into a compound based on predictive ge-
netic models. Similarly, combined inhibition of Kin28
and Srb10 as alleles yields a synergistic inhibition of
RNA-polymerase-II-mediated gene transcription that
cannot be predicted by single-gene inactivation [117].
Why Bother?
It is not easy to use kinase inhibitors to dissect signal-
ing pathways with high selectivity. A great deal of fo-
cused, target-driven chemistry is required to find a sin-
gle potent compound. The scale of this task is such
that the best compounds today are developed largely
by the pharmaceutical industry. Once a potent com-
pound is identified, its selectivity must be extensively
characterized in vitro for it to have any real useful-
ness—and even then, it is impossible to test all of the
potential targets. We have proposed guidelines for
evaluating kinase inhibitor selectivity, but even in the
best case, the possibility of confounding off-target ef-
fects cannot be eliminated.
Is there any good reason to use small-molecule ki-
nase inhibitors rather than competing genetic ap-
proaches such as RNAi? We have emphasized that
these two types of reagents perturb signaling pathways
in different ways and, therefore, can give different out-
comes. Small molecules can inhibit catalytic activity
without affecting other protein domains that might be
disrupted by a knockout. Small molecules are also fast
acting and reversible and, thereby, can escape cellular
compensation that might mask a relevant phenotype.
Perhaps the best reason to use kinase inhibitors to
study signal transduction is so that we might under-
stand the inhibitors themselves. The major barrier todeveloping new drugs is target validation [101, 118]—
the challenge of predicting how inhibition of a target
will translate into phenotype in a physiological setting.
Different types of approaches can contribute to solving
this problem, but pharmacology occupies a privileged
position because it is the ultimate mode of intervention.
No disease can be treated with a mutation (yet), and no
genetic experiment can reliably predict the outcome of
targeting a pathway with a small molecule. For this
reason, it is critical to understand how potent and se-
lective kinase inhibitors function in physiologically rele-
vant model systems, even if the specific molecules
themselves are not destined to be drugs. The emer-
gence of a new generation of kinase inhibitors presents
a unique opportunity to do this—by using these rea-
gents to systematically redefine signaling pathways ac-
cording to their pharmacological properties.
Supplemental Data
Supplemental Data include one figure and Supplemental Ref-
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